The angiotensin II-receptor antagonist losartan does not prevent hemodynamic or vascular tolerance to nitroglycerin

Journal of Cardiovascular Pharmacology

Volumn 34, Issue 5, 1999, Pages 645-650

  Milone, Stephen D ^a   Azevedo, Eduardo R ^a   Forster, Christine ^b   Parker, John D ^a  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Angiotensin II receptor antagonism; Hemodynamics; Nitrate tolerance; Plethysmography

Indexed keywords

GLYCERYL TRINITRATE; LOSARTAN; PLACEBO;

ARTICLE; DRUG TOLERANCE; HEART RATE; HEMODYNAMICS; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; PLETHYSMOGRAPHY; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE;

ADMINISTRATION, CUTANEOUS; ADULT; ANTIHYPERTENSIVE AGENTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG TOLERANCE; HEMATOCRIT; HEMODYNAMIC PROCESSES; HUMANS; LOSARTAN; MALE; NITROGLYCERIN; PLETHYSMOGRAPHY; RECEPTORS, ANGIOTENSIN; VASODILATOR AGENTS;

EID: 0032742062     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199911000-00004     Document Type: Article

References (32)

1. Katz RJ, Levy WS, Buff L, Wasserman AG. Prevention of nitrate tolerance with angiotensin converting enzyme inhibitors. Circulation 1991;83:1271-7.
2. Muiesan ML, Boni E, Castellano M, et al. Effects of transdermal nitroglycerin in combination with an ACE inhibitor in patients with chronic stable angina pectoris. Eur Heart J 1993;14:1701-8.
3. Münzel T, Bassenge E. Long-term angiotensin-converting enzyme inhibition with high dose enalapril retards nitrate tolerance in large epicardial arteries and prevents rebound coronary vasoconstriction in vivo. Circulation 1996;93:2052-8.
4. Pizzulli L, Hagendorff A, Zirbes M, et al. Influence of captopril on nitroglycerin-mediated vasodilation and development of nitrate tolerance in arterial and venous circulation. Am Heart J 1996;131: 342-9.
5. Dupuis J, Lalonde G, Bichet D, Rouleau JL. Captopril does not prevent nitroglycerin tolerance in heart failure. Can J Cardiol 1990;6:281-6.
6. Dakak N, Makhoul N, Flugelman MY, et al. Failure of captopril to prevent nitrate tolerance in congestive heart failure secondary to coronary artery disease. Am J Cardiol 1990;66:608-13.
7. Parker JD, Parker JO. Effect of therapy with an angiotensin-converting enzyme inhibitor on hemodynamic and counterregulatory response during continuous therapy with nitroglycerin. J Am Coll Cardiol 1993;21:1445-53.
8. Münzel T, Sayegh H, Freeman BA, Tarpey MM, Harrison DG. Evidence for enhanced vascular superoxide anion production in nitrate tolerance: a novel mechanism underlying tolerance and cross-tolerance. J Clin Invest 1995;95:187-94.
9. Rajagopalan S, Kurz S, Münzel T, et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation: contribution to alterations of vasomotor tone. J Clin Invest 1996;97:1916-23.
10. Kurz S, Münzel T, Harrison D. A role for angiotensin II in nitrate tolerance: chronic AT-1 receptor blockade prevents development of tolerance and cross tolerance [Abstract]. Circulation 1995;92 (suppl I):I-392.
11. Zelis R, Mason DT. Isosorbide dinitrate: effects on the vasodilator response to nitroglycerin. J Am Med Assoc 1975;234:166-70.
12. Milone SD, Pace-Asciak CR, Reynaud D, Azevedo ER, Newton GE, Parker JD. The effect of nitroglycerin on markers of free radical injury and vitamin C status in humans. J Cardiovasc Pharmacol (in press).
13. Zhenying F, Yunqian L, Dajin L, Yafei L, Fei H, Zhuomin L. Effect of angiotensin converting enzyme inhibitors on tolerance of nitroglycerin. Chin Med J 1995;108:919-22.
14. Mehra A, Ostrzega E, Shotan A, Johnson JV, Elkayam U. Persistent hemodynamic improvement with short term nitrate therapy in patients with chronic congestive heart failure already treated with captopril. Am J Cardiol 1992;70:1310-4.
15. van Gilst WH, de Graeff PA, Scholtens E, de Langen CDJ, Wessling H. Potentiation of isosorbide dinitrate induced coronary dilatation by captopril. J Cardiovasc Pharmacol 1987;9:254-5.
16. Metelitsa VI, Martsevich SY, Kozyreva MP, Slastnikova ID. Enhancement of the efficacy of isosorbide dinitrate by captopril in stable angina pectoris. Am J Cardiol 1992;69:291-6.
17. Meredith IT, Alison JF, Zhang FM, Horowitz JD, Harper RW. Captopril potentiates the effects of nitroglycerin in the coronary vascular bed. J Am Coll Cardiol 1993;22:581-7.
18. Moroi M, Akatsuka N, Fukazawa M, et al. Effect of captopril on acetylcholine-induced relaxation in the presence of nitroglycerin tolerance in isolated rabbit aorta. J Vasc Res 1995;32:347-52.
19. Münzel T, Giaid A, Kurz S, Stewart DJ, Harrison DG. Evidence for a role of endothelin-1 and protein kinase C in nitroglycerin tolerance. Proc Natl Acad Sci U S A 1995;92:5244-8.
20. Parker JD. Counterregulatory responses: sustained-release isosorbide-5-mononitrate versus transdermal nitroglycerin. J Cardiovasc Pharmacol 1996;28:631-8.
21. Doig JK, MacFadyen RJ, Sweet CS, Lees KR, Reid JL. Dose-ranging study of the angiotensin type I receptor antagonist losartan (DuP753/MK954), in salt-deplete normal man. J Cardiovasc Pharmacol 1993;21:732-8.
22. Goldberg MR, Tanaka W, Barchowsky A, et al. Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteers. Hypertension 1993;21:704-13.
23. Christen Y, Waeber B, Nussberger J, et al. Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers: inhibition of pressor response to exogenous angiotensin I and II. Circulation 1991;83:1333-42.
24. Munafro A, Christen Y, Nussberger J, et al. Drug concentration response relationships in normal volunteers after oral administration of losartan: an angiotensin II receptor antagonist. Clin Pharmacol Ther 1992;51:513-21.
25. Goldberg MR, Bradstreet TE, McWilliams EJ, et al. Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients. Hypertension 1995;25:37-46.
26. Lo MW, Goldberg MR, McCrea JB, Lu H, Furtek CI, Bjornsson TD. Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Clin Pharmacol Ther 1995;58:641-9.
27. Gottlieb SS, Dickstein K, Fleck E, et al. Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation 1993;88(pt 1):1602-9.
28. Crozier I, Ikram H, Awan N, et al. Losartan in heart failure: hemodynamic effects and tolerability. Circulation 1995;91:691-7.
29. Dahlöf B, Keller SE, Makris L, Goldberg AI, Sweet CS, Lim NY. Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension. Am J Hypertens 1995;8:578-83.
30. Gradman AH, Arcuri KE, Goldberg AI, et al. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension 1995;25:1345-50.
31. Weber MA, Byyny RL, Pratt JH, et al. Blood pressure effects of the angiotensin II receptor blocker, losartan. Arch Intern Med 1995;155:405-11.
32. Parker JD, Farrell B, Fenton T, Parker JO. Effects of diuretic therapy on the development of tolerance during continuous therapy with nitroglycerin. J Am Coll Cardiol 1992;20:616-22.